StreetInsider.com News Articles

Maravai LifeSciences (MRVI) call put ratio 22 calls to 1 put with a focus on December 5, 7.5 and 10 calls as share price up 25%

Wed, 19 Aug 2026 11:27:05 -0400

Maravai LifeSciences (NASDAQ: MRVI) 30-day call option implied volatility is 131; compared to its 52-week range of 65 to 187. Call put ratio 22 calls to 1 put with a focus on December 5, 7.5 and 10 calls as share price up 25%.

Maravai LifeSciences (MRVI) call put ratio 1 call to 4 puts into share price up before the bell

Wed, 19 Aug 2026 09:15:05 -0400

Maravai LifeSciences (NASDAQ: MRVI) 30-day call option implied volatility is 187; compared to its 52-week range of 65 to 187. Call put ratio 1 call to 4 puts.

Form SCHEDULE 13G/A MARAVAI LIFESCIENCES Filed by: FELDMAN STUART

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921901.html

Form SCHEDULE 13G/A MARAVAI LIFESCIENCES Filed by: FELDMAN STUART

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921901.html

Form 4 MARAVAI LIFESCIENCES For: Aug 10 Filed by: Brust Bernd

Tue, 11 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260811/26906646.html

Form 4 MARAVAI LIFESCIENCES For: Aug 10 Filed by: Brust Bernd

Tue, 11 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260811/26906646.html

Form 10-Q MARAVAI LIFESCIENCES For: Jun 30

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890911.html

Form 10-Q MARAVAI LIFESCIENCES For: Jun 30

Fri, 07 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260807/26890911.html

Maravai LifeScience Holdings Inc. (MRVI) PT Raised to $6.50 at Wells Fargo

Fri, 07 Aug 2026 08:24:06 -0400

Wells Fargo analyst Evan Stampler raised the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $6.50 (from $5.50) while maintaining a Overweight rating.

Maravai LifeSciences (MRVI) Tops Q2 EPS by 2c

Thu, 06 Aug 2026 16:26:54 -0400

Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.02), $0.02 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $51.4 million versus the consensus estimate of $48.68 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

Form 8-K MARAVAI LIFESCIENCES For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883685.html

Form 8-K MARAVAI LIFESCIENCES For: Aug 06

Thu, 06 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26883685.html

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

SAN DIEGO--(BUSINESS WIRE)-- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2026, together with other business updates.

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the

Maravai LifeSciences Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:01:00 -0400

Second quarter 2026 total revenue up 9% from prior year

Key Financial Results:

Quarterly revenue of $51.4 million, Net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million;
Full year 2026 Adjusted EBITDA guidance raised to $33 million to $35 million; Reiterating 2026 revenue guidance range of $205 million to $215 million.

“Our second quarter results reflect the